Scott Antonia

Parker Institute for Cancer Immunotherapy

Also affiliated with Duke Medical Center, Duke Cancer Institute

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 15 papers. Top paper: “Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial”.

Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial

Journal of Thoracic Oncology(2021)10.1016/j.jtho.2020.12.015

N/A

6.9DataRank · unranked

471 citations

David Vicente, Takayasu Kurata, David Planchard, Luis Paz‐Ares, Johan Vansteenkiste +18 more

Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-2742

N/A

1.8DataRank · unranked

70 citations

Ben Creelan, Tawee Tanvetyanon, Jhanelle E. Gray, Eric B. Haura, Ram Thapa +13 more

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

New England Journal of Medicine(2015)10.1056/nejmoa1507643

N/A

1.4DataRank · unranked

9414 citations

Luis Paz-Ares, Diane P Holder, David R. Spigel, Martin Steins, Neal E. Ready +38 more

Characterization of Sentinel Lymph Node Immune Signatures and Implications for Risk Stratification for Adjuvant Therapy in Melanoma

Annals of Surgical Oncology(2020)10.1245/s10434-020-09277-w

N/A

0DataRank · unranked

19 citations

Eda K. Holl, Jeanne Jung, Junheng Gao, Sin‐Ho Jung, Rami N. Al‐Rohil +8 more

Systematic review of combinations of targeted or immunotherapy in advanced solid tumors

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002459

N/A

0DataRank · unranked

83 citations

Stephen Bagley, Patrick Y. Wen, Michael Lim, Michael Platten, Howard Colman +16 more

A micro-organosphere potency assay for adoptive T-cell therapy.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.e15027

N/A

0DataRank · unranked

0 citations

Shengli Ding, Golshid Sanati, Shiaowen David Hsu, Scott Antonia, Xiling Shen +1 more

Patient-derived micro-organospheres enable clinical precision oncology

Cell stem cell(2022)10.1016/j.stem.2022.04.006

N/A

0DataRank · unranked

214 citations

Carolyn Hsu, Zhaohui Wang, Naveen Natesh, Rosemary Millen, Marcos Negrete +32 more

Peroxynitrite in the tumor microenvironment changes the profile of antigens allowing escape from cancer immunotherapy

Cancer Cell(2022)10.1016/j.ccell.2022.09.001

N/A

0DataRank · unranked

52 citations

Emilio Sanseviero, Douglas Marvel, Thomas Beer, Hsin‐Yao Tang, Peter Hembach +26 more

Data from Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

(2023)10.1158/1078-0432.c.6531020

N/A

0DataRank · unranked

0 citations

Ben Creelan, Tawee Tanvetyanon, Jhanelle E. Gray, Eric B. Haura, R. K. Thapa +13 more

Data from Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

(2023)10.1158/1078-0432.c.6531020.v1

N/A

0DataRank · unranked

0 citations

Ben Creelan, Tawee Tanvetyanon, Jhanelle E. Gray, Eric B. Haura, R. K. Thapa +13 more

Oncolytic adenovirus MEM-288 encoding membrane-stable CD40L and IFNβ induces an anti-tumor immune response in high grade serous ovarian cancer

Neoplasia(2024)10.1016/j.neo.2024.101056

N/A

0DataRank · unranked

13 citations

Regina S. Whitaker, Felicia Lim, Shonagh Russell, Elizabeth A. Bloom, Justin Pollara +7 more

Differential roles of normal and lung cancer-associated fibroblasts in microvascular network formation

APL Bioengineering(2024)10.1063/5.0188238

N/A

0DataRank · unranked

10 citations

Pankaj Mogha, Alan Chen, Scott Antonia, Shyni Varghese, Naveen Natesh

Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): conventional and distribution-based immune profiling of the tumor microenvironment and peripheral circulation

Journal for ImmunoTherapy of Cancer(2025)10.1136/jitc-2025-012432

N/A

0DataRank · unranked

0 citations

Lin Lin, Jennifer Enzor, Prekshaben Patel, Katelyn N. Steadman, Victoria E Little +7 more

Sirt2 Inhibition Enhances Metabolic Fitness and Effector Functions of Tumor-Reactive T Cells

Cell Metabolism(2020)10.1016/j.cmet.2020.07.008

N/A

0DataRank · unranked

162 citations

Lin Zhang, Nayoung Kim, Min-Hsuan Wang, Cristina Iclozan, Bin Fang +12 more

A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC

Journal of Thoracic Oncology(2020)10.1016/j.jtho.2020.11.021

N/A

0DataRank · unranked

62 citations

Angela Hu, Scott Antonia, Chuan‐Yuan Li, Dong Pan